Skip to main content

Advertisement

SpringerLink
Log in

Understanding the Impact of National and State Medical Marijuana Policies on Adolescents

  • Adolescent / Young Adult Addiction (T Chung, Section Editor)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This article provides an overview of current federal, state, and relevant international “medical marijuana” policies. We also describe the impacts of “medical marijuana” policy on adolescents’ use of marijuana and other substances.

Recent Findings

Evidence on the medical benefits of marijuana in adolescents is limited in the context of risks for marijuana-related harm. The legalization of marijuana for medical purposes is associated with a decrease in marijuana risk perception in older adolescents. Marijuana-related harms have increased in states that have legalized marijuana for medical purposes or adult use.

Summary

The long-term impacts on adolescents of marijuana policies for medical purposes or adult use remain poorly understood. Marijuana policy changes that liberalize access may increase rates of youth marijuana use. There is an important need for high quality research and open sharing of best practices regarding marijuana policies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Centers for Disease Control and Prevention. Fact Sheets - Age 21 Minimum Legal Drinking Age [Internet]. 2017 [cited 2017 Nov 25]. Available from: https://www.cdc.gov/alcohol/fact-sheets/minimum-legaldrinking-age.htm.

  2. Albertson TE, Chenoweth JA, Colby DK, Sutter ME. The changing drug culture: medical and recreational marijuana. FP Essent. 2016;441:11–7.

    PubMed  Google Scholar 

  3. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Johnston L, O’Malley P, Miech R, Bachman J, Schulenberg J. Monitoring the future national survey results on drug use, 1975–2016: overview, key findings on adolescent drug use. Monitoring the future: national survey results on drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2017.

    Google Scholar 

  5. Friese B, Slater MD, Annechino R, Battle RS. Teen use of marijuana edibles: a focus group study of an emerging issue. J Prim Prev [Internet]. 2016 Jun 7 [cited 2017 Dec 3];37(3):303–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27056685.

  6. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev. 2010;29(3):318–30.

    Article  PubMed  Google Scholar 

  7. Rieder MJ. Is the medical use of cannabis a therapeutic option for children? Paediatr Child Health. 2016;21(1):31–4.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME, Johnston LD. Monitoring the Future national survey results on drug use, 1975–2016., vol. I. Ann Arbor: Institue for Social Research: The University of Michigan; 2017.

    Google Scholar 

  9. Patrick ME, Bray BC, Berglund PA. Reasons for marijuana use among young adults and long-term associations with marijuana use and problems. J Stud Alcohol Drugs [Internet]. 2016 [cited 2017 Nov 24];77(6):881–8. Available from: http://www.jsad.com/doi/10.15288/jsad.2016.77.881

  10. Medical Marijuana Registry Program Statistics-September 2017 [Internet]. 2017. Available from: https://www.colorado.gov/pacific/sites/default/files/CHED_MMR_Monthly_Report-SEPTEMBER-2017.pdf

  11. King KA, Merianos AL, Vidourek RA. Characteristics of marijuana acquisition among a national sample of adolescent users. Am J Heal Educ [Internet]. 2016 [cited 2017 Nov 11];47(3):126–35. Available from: https://www.tandfonline.com/doi/full/10.1080/19325037.2016.1157535

  12. Osilla KC, Pedersen ER, Ewing BA, Miles JN V, Ramchand R, D’Amico EJ. The effects of purchasing alcohol and marijuana among adolescents at-risk for future substance use. Subst Abuse Treat Prev Policy [Internet]. 2014 [cited 2017 Nov 24];9:38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25231097.

  13. Thurstone C, Lieberman SA, Schmiege SJ. Medical marijuana diversion and associated problems in adolescent substance treatment. Drug Alcohol Depend [Internet]. 2011 [cited 2017 Nov 12];118(2–3):489–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21565453.

  14. Boyd CJ, Veliz PT, McCabe SE. Adolescents’ use of medical marijuana: a secondary analysis of monitoring the future data. J Adolesc Health [Internet]. 2015 [cited 2017 Nov 12];57(2):241–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26206447.

  15. • Shi Y. The availability of medical marijuana dispensary and adolescent marijuana use. Prev Med. 2016;91:1–7. This article identified an increase in non-medical use of marijuana in younger adolescents living in close proximity of medical marijuana dispensaries.

    Article  PubMed  Google Scholar 

  16. Bierut T, Krauss MJ, Sowles SJ, Cavazos-Rehg PA. Exploring marijuana advertising on Weedmaps, a popular online directory. Prev Sci [Internet]. 2017 [cited 2017 Nov 24];18(2):183–92. Available from: http://link.springer.com/10.1007/s11121-016-0702-z

  17. Radwan MM, ElSohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high-potency Cannabis sativa. J Nat Prod [Internet]. 2009;72(5):906–11. https://doi.org/10.1021/np900067k.

    Article  CAS  Google Scholar 

  18. • Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther [Internet]. 2017;22(3):176–85. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473390/. This article reviews the potential benefits and harms of cannabinoids in pediatrics and emphasizes the need for additional research in this area.

    Google Scholar 

  19. Johns A. Psychiatric effects of cannabis. Br J Psychiatry [Internet]. 2001 [cited 2017 Dec 3];178:116–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11157424.

  20. Simpson AK, Magid V. Cannabis use disorder in adolescence. Child Adolesc Psychiatr Clin N Am. 2016;25(3):431–43.

    Article  PubMed  Google Scholar 

  21. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20(Suppl 1):10–4.

    Article  PubMed  CAS  Google Scholar 

  22. Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad Sci [Internet]. 2008;1124(1):111–26. https://doi.org/10.1196/annals.1440.010.

    Article  PubMed Central  CAS  Google Scholar 

  23. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. • Lubman DI, Cheetham A, Yücel M. Cannabis and adolescent brain development. Pharmacol Ther [Internet]. 2015 [cited 2017 Dec 15];148:1–16. Available from: http://www.sciencedirect.com/science/article/pii/S0163725814002095. This article provides important insights on the effects of marijuana use on the developing adolescent brain.

  25. Price JS, McQueeny T, Shollenbarger S, Browning EL, Wieser J, Lisdahl KM. Effects of marijuana use on prefrontal and parietal volumes and cognition in emerging adults. Psychopharmacology (Berl) [Internet]. 2015 [cited 2017 Dec 3];232(16):2939–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25921032.

  26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington DC; 2000.

  27. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A [Internet]. 2012 [cited 2017 Nov 25];109(40):E2657–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22927402.

  28. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, et al. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci [Internet]. 2016 [cited 2017 Nov 24];113(5):E500–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26787878.

  29. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS report: age of substance use initiation among treatment admissions Aged 18 to 30 [Internet]. Rockville, MD; 2017 [cited 2017 Nov 10]. Available from: https://www.samhsa.gov/data/sites/default/files/WebFiles_TEDS_SR142_AgeatInit_07-10-14/TEDS-SR142-AgeatInit-2014.pdf

  30. Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry [Internet]. 2007 [cited 2017 Nov 10];20(4):393–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17551355.

  31. Grant CN, Bélanger RE. Cannabis and Canada’s children and youth. Paediatr Child Health [Internet]. 2017;22(2):98–102. https://doi.org/10.1093/pch/pxx017.

    Article  Google Scholar 

  32. Bechtold J, Hipwell A, Lewis DA, Loeber R, Pardini D. Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms. Am J Psychiatry [Internet]. 2016 [cited 2017 Dec 5];173(8):781–9. Available from: http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2016.15070878

  33. Marie O, Zölitz U. “High” Achievers? Cannabis Access and Academic Performance. Rev Econ Stud [Internet]. 2017 [cited 2017 Nov 10];84(3):1210–37. Available from: https://academic.oup.com/restud/article-lookup/doi/10.1093/restud/rdx020

  34. Hadland SE, Harris SK. Youth marijuana use: state of the science for the practicing clinician. Curr Opin Pediatr. 2014;26(4):420–7.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol [Internet]. 2017 [cited 2017 Nov 24];80(3):441–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28780725.

  36. Elder JJ, Knoderer HM. Characterization of dronabinol usage in a pediatric oncology population. J Pediatr Pharmacol Ther [Internet]. 2015 [cited 2017 Nov 25];20(6):462–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26766935.

  37. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics [Internet]. 1987 [cited 2017 Nov 25];79(6):946–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3035479.

  38. • Ammerman S, Ryan S, Adelman WP. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3):e769–85. This detailed technical report summarizes the position of the American Academy of Pediatrics on current marijuana legalization policies and provides key insights on effects of these policies on children and adolescents.

    Article  PubMed  Google Scholar 

  39. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol [Internet]. 2016[cited 2017 Nov 25];15(3):270–8. Available from: http://www.sciencedirect.com/science/article/pii/S1474442215003798

  40. • Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics [Internet]. 2017 [cited 2017 Nov 6];e20171818. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29061872. This review article summarizes current evidence on the medical use of cannabinoids in children and adolescents and draws parallels with potential adverse mental health effects identified in studies that looked at adolescent cannabis use in non-medical settings.

  41. US Department of Justice Drug Enforcement Administration Diversion Control Division. Title 21 Code of Federal Regulations-Part 1308-Schedules of Controlled Substances [Internet]. [cited 2017 Nov 25]. Available from: https://www.deadiversion.usdoj.gov/21cfr/cfr/2108cfrt.htm

  42. Ogden DW. Memorandum for selected United State attorneys on investigations and prosecutions in states Authorizing the Medical Use of Marijuana|OPA|Department of Justice [Internet]. 2009 [cited 2017 Nov 25]. Available from: https://www.justice.gov/archives/opa/blog/memorandum-selected-united-state-attorneys-investigations-and-prosecutions-states

  43. Cole JM. Memorandum for United States Attorneys. Guidance regarding the Ogden memo in jurisdictions seeking to authorize marijuana for medical use [Internet]. 2011 [cited 2017 Nov 25]. Available from: https://www.justice.gov/sites/default/files/oip/legacy/2014/07/23/dag-guidance-2011-for-medical-marijuana-use.pdf

  44. Cole JM. Guidance regarding Marijuana Enforcement. Fed Sentencing Report [Internet]. 2013 [cited 2017 Nov 25];26. Available from: https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf

  45. National Conference of State Legislatures. State Medical Marijuana Laws [Internet]. 2017 [cited 2017 Nov 25]. Available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

  46. Kilmer B. Recreational cannabis—minimizing the health risks from legalization. N Engl J Med [Internet]. 2017;376(8):705–7. https://doi.org/10.1056/NEJMp1614783.

    Article  Google Scholar 

  47. National Conference of State Legislatures. Marijuana overview. 2017.

  48. Inchley J, Currie D Dorothy B, Young T, Samdal O, Torsheim T, Augustson L, et al. Growing up unequal: gender and socioeconomic differences in young people’s health and well-being. Health Behaviour in School-Aged Children (HBSC) Study: international report from the 2013/2014 survey. 276 p.

  49. Administration SA and MHS. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. (HHS Publication No. SMA 17-5044 NSH-52), editor. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.

  50. Miech R, Johnston L, O’Malley PM. Prevalence and attitudes regarding marijuana use among adolescents over the past decade. Pediatrics [Internet]. 2017 [cited 2017 Nov 10];e20170982. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29109106.

  51. Chadi N, Levy S. Understanding the highs and lows of adolescent marijuana use. Pediatrics [Internet]. 2017 [cited 2017 Nov 10];e20173164. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29109105.

  52. Keyes KM, Wall M, Cerdá M, Schulenberg J, O’Malley PM, Galea S, et al. How does state marijuana policy affect US youth? Medical marijuana laws, marijuana use and perceived harmfulness: 1991–2014. Addiction [Internet]. 2016;111(12):2187–95. https://doi.org/10.1111/add.13523.

    Article  Google Scholar 

  53. Harper S, Strumpf EC, Kaufman JS. Do medical marijuana laws increase marijuana use? Replication study and extension. Ann Epidemiol. 2012;22(3):207–12.

    Article  PubMed  Google Scholar 

  54. Choo EK, Benz M, Zaller N, Warren O, Rising KL, McConnell KJ. The impact of state medical marijuana legislation on adolescent marijuana use. J Adolesc Health. 2014;55(2):160–6.

    Article  PubMed  Google Scholar 

  55. • Cerda M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, et al. Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr. 2017;171(2):142–9. This article reports changes in perception of risk and rates of marijuana use in adolescents in the states of Washington and Colorado following the legalization of marijuana for adult use.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hasin DS, Wall M, Keyes KM, Cerda M, Schulenberg J, O’Malley PM, et al. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry. 2015;2(7):601–8.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Mauro CM, Newswanger P, Santaella-Tenorio J, Mauro PM, Carliner H, Martins SS. Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004–2013. Prev Sci [Internet]. 2017 [cited 2017 Dec 13];1–10. Available from: http://link.springer.com/10.1007/s11121-017-0848-3

  58. Levy S, Weitzman ER. Building a learning marijuana surveillance system. JAMA Pediatr. 2016;170(3):193–4.

    Article  PubMed  Google Scholar 

  59. • Pacula RL, Smart R. Medical marijuana and marijuana legalization. Annu Rev Clin Psychol. 2017;13:397–419. This review article provides key insights on the limitations of the current literature on marijuana legalization and how research findings to date should be interpreted with caution.

    Article  PubMed  Google Scholar 

  60. Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP. Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health [Internet]. 2014;104(6):1021–8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062005/

    Article  Google Scholar 

  61. Johnson J, Hodgkin D, Harris SK. The design of medical marijuana laws and adolescent use and heavy use of marijuana: Analysis of 45 states from 1991 to 2011. Drug Alcohol Depend. 2017;170:1–8.

    Article  PubMed  Google Scholar 

  62. Wang JB, Ramo DE, Lisha NE, Cataldo JK. Medical marijuana legalization and cigarette and marijuana co-use in adolescents and adults. Drug Alcohol Depend. 2016;166:32–8.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Guttmannova K, Lee CM, Kilmer JR, Fleming CB, Rhew IC, Kosterman R, et al. Impacts of changing marijuana policies on alcohol use in the United States. Alcohol Clin Exp Res. 2016;40(1):33–46.

    Article  PubMed  Google Scholar 

  64. • Wen H, Hockenberry JM, Cummings JR. The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J Heal Econ. 2015;42:64–80. Looking at data from 2004 to 2012 in ten states with medical marijuana laws, this article identifies increases in marijuana use initiation in adolescents as well as increases in marijuana use and rates of binge drinking in adults.

    Article  Google Scholar 

  65. Moss HB, Chen CM, Yi H. Early adolescent patterns of alcohol, cigarettes, and marijuana polysubstance use and young adult substance use outcomes in a nationally representative sample. Drug Alcohol Depend [Internet]. 2014 Mar [cited 2017 Nov 18];136:51–62. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0376871613005279

  66. • Rocky Mountain High Intensity Drug Trafficking Area. The Legalization of Marijuana in Colorado, The Impact. Vol. 4. 2016. This report provides a detailed analysis of the effects of the legalization of marijuana in Colorado and outlines important increases in marijuana-related harms for youth following legalization of marijuana for medical purposes and adult use.

  67. Hadland SE, Xuan Z, Sarda V, Blanchette J, Swahn MH, Heeren TC, et al. Alcohol policies and alcohol-related motor vehicle crash fatalities among young people in the US. Pediatrics [Internet]. 2017;139(3). Available from: https://www.ncbi.nlm.nih.gov/pubmed/28193794.

  68. National Highway Traffic Safety Administration. Marijuana-impaired driving—a report to congress [Internet]. 2017 [cited 2017 Dec 13]. Available from: https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-driving-report-to-congress.pdf

  69. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem [Internet]. 2013 [cited 2017 Nov 24];59(3):478–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23220273.

  70. Northwest High Intensity Drug Trafficking Area. Marijuana Impact Report, Washington State [Internet]. 2017 [cited 2017 Nov 24]. Available from: https://hidtanmidotorg.files.wordpress.com/2017/09/nwhidta-marijuana-impact-report-volume-2_august-2017.pdf

  71. Hopfer C. Implications of marijuana legalization for adolescent substance use. Subst Abus. 2014;35(4):331–5.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Sevigny EL, Pacula RL, Heaton P. The effects of medical marijuana laws on potency. Int J Drug Policy. 2014;25(2):308–19.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry [Internet]. 2009 [cited 2017 Nov 24];195(6):488–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19949195.

  74. Hazelden Betty Ford Institute for Recovery Advocacy and the University of Maryland School of Public Health. Concerns rising over high-potency marijuana use [Internet]. 2017. Available from: file:///C:/Users/CH193486/Downloads/60035_EmergingTrendsReport_WhitePaper_Singlepages_FxLR.pdf

  75. Hajizadeh M. Legalizing and regulating marijuana in Canada: review of potential economic, social, and health impacts. Int J Heal Policy Manag [Internet]. 2016 [cited 2017 Nov 24];5(8):453–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27694657.

  76. Hazelden Betty Ford Institute for Recovery Advocacy and the University of Maryland School of Public Health. Concerns Rising Over High-Potency Marijuana Use. 2017.

  77. • Hadland SE, Knight JR, Harris SK. Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. J Dev Behav Pediatr. 2015;36(2):115–23. This article describes neurocognitive changes associated with the use of marijuana in youth with developmental and behavioral disorders and discusses potential risks and benefits of medical use of marijuana in this population.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Andreae MH, Rhodes E, Bourgoise T, Carter GM, White RS, Rhodes R. An ethical exploration of barriers to research on controlled drugs. [cited 2017 Dec 13]; Available from: http://www.tandfonline.com/doi/pdf/10.1080/15265161.2016.1145282

  79. Neale M. Efficacy and safety of cannabis for treating children with refractory epilepsy. Nurs Child Young People [Internet]. 2017 [cited 2017 Dec 5];29(7):32–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29115760.

  80. Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy. Seizure [Internet]. 2016 [cited 2017 Nov 18];35:41–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26800377.

  81. Volkow ND, Koob GF, Croyle RT, Bianchi DW, Gordon JA, Koroshetz WJ, et al. The conception of the ABCD study: from substance use to a broad NIH collaboration. Dev Cogn Neurosci [Internet]. 2017 [cited 2017 Nov 18]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29051027.

  82. American Academy of Child and Adolescent Psychiatry. AACAP Medical Marijuana Policy Statement [Internet]. 2012. Available from: http://www.aacap.org/AACAP/Policy_Statements/2012/AACAP_Medical_Marijuana_Policy_Statement.aspx

  83. American Society of Addiction Medicine. Public Policy Statement on Marijuana, Cannabinoids and Legalization. 2015 [cited 2017 Nov 18]; Available from: https://www.asam.org/docs/default-source/public-policy-statements/marijuana-cannabinoids-and-legalization-9-21-2015.pdf?sfvrsn=0

Download references

Author information

Authors and Affiliations

  1. Division of Developmental Medicine, Boston Children’s Hospital, Boston, MA, USA

    Nicholas Chadi & Sharon Levy

  2. Division of Adolescent/Young Adult Medicine, Boston Children’s Hospital, Boston, MA, USA

    Nicholas Chadi & Elissa R. Weitzman

  3. Department of Pediatrics, Harvard Medical School, Boston, MA, USA

    Nicholas Chadi, Elissa R. Weitzman & Sharon Levy

  4. Adolescent Substance Use and Addiction Program, Boston Children’s Hospital/Harvard Medical School, 300 Longwood Avenue, Boston, MA, 02115, USA

    Nicholas Chadi & Sharon Levy

Authors
  1. Nicholas Chadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elissa R. Weitzman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sharon Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas Chadi.

Ethics declarations

Conflict of Interest

Nicholas Chadi has served voluntarily on the Massachusetts Cannabis Control Advisory Board.

Elissa R. Weitzman declares that she has no conflict of interest.

Sharon Levy has served voluntarily on the Massachusetts Cannabis Control Advisory Board.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Adolescent/Young Adult Addiction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chadi, N., Weitzman, E.R. & Levy, S. Understanding the Impact of National and State Medical Marijuana Policies on Adolescents. Curr Addict Rep 5, 93–101 (2018). https://doi.org/10.1007/s40429-018-0191-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-018-0191-1

Keywords

Search

Navigation